Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $39.11 USD
Change Today +0.71 / 1.85%
Volume 250.1K
PTLA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

portola pharmaceuticals inc (PTLA) Snapshot

Open
$38.53
Previous Close
$38.40
Day High
$39.15
Day Low
$38.02
52 Week High
03/4/15 - $43.63
52 Week Low
05/21/14 - $19.59
Market Cap
2.0B
Average Volume 10 Days
293.3K
EPS TTM
$-3.19
Shares Outstanding
51.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PORTOLA PHARMACEUTICALS INC (PTLA)

Related News

No related news articles were found.

portola pharmaceuticals inc (PTLA) Related Businessweek News

No Related Businessweek News Found

portola pharmaceuticals inc (PTLA) Details

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III clinical trial for venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge. The company’s other lead development candidate, Andexanet alfa, a recombinant protein that is in Phase III registration studies designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Lee’s Pharmaceutical (HK) Ltd. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. The company was founded in 2003 and is headquartered in South San Francisco, California.

99 Employees
Last Reported Date: 03/2/15
Founded in 2003

portola pharmaceuticals inc (PTLA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $415.5K
Executive Vice President and Head of Research...
Total Annual Compensation: $463.3K
Compensation as of Fiscal Year 2013.

portola pharmaceuticals inc (PTLA) Key Developments

Nicholas Galakatos Intends Not to Stand for Reelection as Director of Portola Pharmaceuticals

On April 9, 2015 Nicholas Galakatos, a member of the Board of Directors of Portola Pharmaceuticals, Inc. informed the company that he does not intend to stand for reelection at the company’s 2015 annual meeting of stockholders. He advised the Board that his decision was not related to any disagreement with the Company’s operations, policies, or practices. Dr. Galakatos will continue to serve as director and member of the Audit and Compensation Committees until the Company’s 2015 Annual Meeting of Stockholders. Dr. Galakatos joined the Board in 2003.

Portola Pharmaceuticals Announces New Data From Phase 3 ANNEXA-A(TM) Trial Part 2

Portola Pharmaceuticals announced positive results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study, which evaluated the safety and efficacy of andexanet alfa, an investigational antidote, with the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers. Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, was administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity. This registration-enabling study achieved all primary and secondary endpoints with high statistical significance. Andexanet alfa produced rapid reversal of the anticoagulant effect of apixaban, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. In the study, andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa reported. The full data from this second part of the ANNEXA-A study will be presented at an upcoming scientific meeting. Portola plans to submit data from the ANNEXA-A (apixaban) and ANNEXA-R (rivaroxaban) studies, and initial data from a Phase 4 study, as part of its Biologics License Application to the FDA under an Accelerated Approval pathway by the end of 2015. ANNEXA-A Study Design: The randomized, double-blind, placebo-controlled Phase 3 ANNEXA-A study evaluated the safety and efficacy of andexanet alfa in reversing apixaban-induced anticoagulation in older healthy volunteers ages 50-75 years. Efficacy was evaluated using biomarker endpoints, with anti-Factor Xa levels as the primary endpoint. Secondary endpoints included plasma levels of free unbound apixaban and endogenous thrombin potential (ETP), a measure of thrombin generation. In the first part of the study, which was previously presented, 33 healthy volunteers were given apixaban 5 mg twice daily for four days and then randomized in a 3:1 ratio to andexanet alfa administered as a 400 mg IV bolus (n=24) or to placebo (n=9). Portola announced topline results from the second part of the study, in which 31 healthy volunteers were given apixaban 5 mg twice daily for four days and then randomized in a 3:1 ratio to andexanet alfa administered as a 400 mg IV bolus followed by a continuous infusion of 4 mg/min for 120 minutes (n=23) or to placebo (n=8). Results of First Part of ANNEXA-A Study: Results from the first part of the ANNEXA-A study were presented during an oral session at the American Heart Association (AHA) 2014 Scientific Sessions in Chicago in November 2014. The first part of the study achieved all primary and pre-specified secondary endpoints with statistical significance (p< 0.0001). Andexanet alfa administered as an IV bolus produced rapid and nearly complete reversal of the anticoagulant effect of apixaban. Two to five minutes after completion of a bolus dose of andexanet alfa, the anticoagulant activity of apixaban was reversed by approximately 94% (p< 0.0001) compared with placebo as measured by anti-Factor Xa activity. Every subject treated with andexanet alfa had between 90 and 96% reversal of the anticoagulant activity of apixaban. No serious adverse events, thrombotic events, or antibodies to Factor X or Xa were reported following andexanet alfa administration. Mild infusion reaction was reported in three subjects. Addressing the Absence of a Factor Xa Inhibitor Antidote: Currently, millions of patients are treated with Factor Xa inhibitors for short-term use or chronic conditions, and the anticoagulant market is expected to continue to grow. Recent patient datai confirm earlier clinical trial results showing that, annually, between 1 to 4% of patients treated with Factor Xa inhibitors may experience major bleeding and an additional 1% may require emergency surgery. Development of a specific antidote designed to reverse the anticoagulant activity of Factor Xa inhibitors may provide an important treatment option for patients who experience a major bleeding event or require emergency surgery.

Portola Pharmaceuticals, Inc. Announces Results from Positive Phase 3 ANNEXA(Tm)-R Study

Portola Pharmaceuticals announced full results from the first part of the Phase 3 ANNEXA™-R study, which is evaluating the safety and efficacy of andexanet alfa with the Factor Xa inhibitor XARELTO® (rivaroxaban) in healthy volunteers. Results showed the first part of this registration-enabling study met all primary and secondary endpoints with high statistical significance (p<0.0001 compared with placebo). Andexanet alfa administered as an intravenous (IV) bolus produced rapid and significant reversal of the anticoagulant effect of XARELTO® as measured by anti-Factor Xa activity (>90% reduction of mean anti-Factor Xa activity within five minutes of the end of administration). Additionally, there was a significant reduction in the level of free (unbound) XARELTO® in the plasma, and thrombin generation was rapidly restored to within the normal baseline range following administration of andexanet alfa. In the study, andexanet alfa was well tolerated. There were no serious or severe adverse events, no thrombotic events, and no antibodies to Factor X or Xa observed. The randomized, double-blind, placebo-controlled Phase 3 ANNEXA-R study is evaluating the safety and efficacy of andexanet alfa in reversing XARELTO®-induced anticoagulation in healthy volunteers ages 50-75 years. Efficacy is being evaluated using biomarker endpoints, with anti-Factor Xa levels as the primary endpoint. Secondary endpoints include plasma levels of free unbound XARELTO® and endogenous thrombin potential (ETP), a measure of thrombin generation. In the first part of the ANNEXA-R study, 41 healthy volunteers were given XARELTO® 20 mg once daily for four days to steady state. They were then randomized in a 2:1 ratio to receive at Cmax either andexanet alfa administered as an 800 mg IV bolus (n=27) or placebo (n=14). Results showed that, for the primary endpoint, andexanet alfa reduced the anti-Factor Xa activity of rivaroxaban from baseline to nadir by >90%, a highly significant difference (p<0.0001). For the secondary endpoints: Significantly more andexanet alfa subjects (26 of 27) than placebo subjects (0) had a 90% or greater reduction in anti-Factor Xa activity from baseline to nadir (p<0.0001). The free (unbound) XARELTO® concentration from baseline to nadir was reduced significantly by andexanet alfa compared with placebo (p<0.0001). ETP significantly increased from baseline to peak in andexanet alfa subjects compared with placebo subjects (p<0.0001). 26 of 27 andexanet alfa subjects returned to the normal range of thrombin generation within 10 minutes of the end of the bolus administration. In the study, andexanet alfa was well tolerated. There were no serious or severe adverse events, no thrombotic events, and no antibodies to Factor X or Xa were observed. In the second part of the ANNEXA-R study, approximately 40 healthy volunteers will be given XARELTO® 20 mg once daily for four days and will then be randomized in a 2:1 ratio to receive either andexanet alfa administered as an 800 mg IV bolus followed by a continuous infusion of 8 mg/min for 120 minutes or to placebo. Data from this part of the study are expected in mid-2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTLA:US $39.11 USD +0.71

PTLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTLA.
View Industry Companies
 

Industry Analysis

PTLA

Industry Average

Valuation PTLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 192.1x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 172.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PORTOLA PHARMACEUTICALS INC, please visit www.portola.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.